The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Describing the genomic landscape of bladder cancer histologic subtypes.
 
Rafee Talukder
No Relationships to Disclose
 
Rachel Berg
Employment - Tempus
 
Minxuan Huang
Employment - Tempus
Consulting or Advisory Role - ZS Associates
 
Vanessa M. Nepomucino
Employment - Tempus
Stock and Other Ownership Interests - Tempus
 
Melissa Conrad Stoppler
Employment - Gilead Sciences (I); Roche/Genentech (I); Roche/Genentech (I); Tempus
Stock and Other Ownership Interests - Exact Sciences; Gilead Sciences (I); Roche/Genentech (I); Tempus
 
Dimitrios Makrakis
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Aihua Edward Yen
Consulting or Advisory Role - AVEO; Dendreon
Travel, Accommodations, Expenses - Carden Jennings; Carden Jennings
 
Martha P. Mims
Stock and Other Ownership Interests - Amgen; Biogen
Research Funding - AVEO (Inst); Celgene; Pfizer (Inst)
 
Seth P. Lerner
Stock and Other Ownership Interests - Aura Biosciences; C2i genomics
Honoraria - Grand Rounds in Urology; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb Foundation/Janssen; C2i Genomics; Ferring; Pfizer/EMD Serono; Protara Therapeutics; Stimit; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate
 
Solomon L. Woldu
Consulting or Advisory Role - Urogen pharma
 
Yair Lotan
Stock and Other Ownership Interests - C2i genomics; CAPs medical; Nanorobotics; Phinomics; Uroviu; Vessi Medical; Virtuoso Therapeutics
Consulting or Advisory Role - Abbvie; Ambu; AstraZeneca; Aura Biosciences; BMS; C2i genomics; caps medical; Cleveland Diagnostics; Convergent Genomics; Fergene; Merck; Nanogen Biopharmaceutical; Nanorobotics; Nucleix; pacific edge; phinomics; Photocure; Seagen; Stimit; Urogen pharma; uroviu; verity pharmaceuticals; Vessi Medical; virtuoso surgical; Xcures
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst); storz (Inst)
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
 
Ali Raza Khaki
Honoraria - HMP; OncLive/MJH Life Sciences
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - 23andMe (Inst); Janssen Oncology (Inst)
Other Relationship - Tempus
(OPTIONAL) Uncompensated Relationships - Janssen; Seattle Genetics/Astellas
 
Jeanny B. Aragon-Ching
Honoraria - Astellas Scientific and Medical Affairs Inc; Bristol-Myers Squibb; EMD Serono; Merck KGaA; Merck/Pfizer; Pfizer/EMD Serono
Consulting or Advisory Role - Algeta/Bayer; Amgen; AstraZeneca; AstraZeneca/MedImmune; AVEO; Bayer; Dendreon; EMD Serono; Exelixis; Immunomedics; Janssen Biotech; Merck; Pfizer; Pfizer/Myovant; Sanofi; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Algeta/Bayer; Astellas Pharma; Bristol Myers Squibb; Dendreon; EMD Serono
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Fresenius Kabi; G1 Therapeutics; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Pfizer; PureTech; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)